Jared Baeten, MD, PhD

Gilead Sciences
Foster City, California, United States

Disclosure(s): Gilead Sciences, Inc.: employee and shareholder

Presentation(s):

• 577 - Week 48 Results of a Phase 2 Study Evaluating Once-weekly Oral Islatravir Plus Lenacapavir

  Saturday, October 19, 2024
  2:09 PM – 2:21 PM US PT